NYUHSL Faculty Bibliography

Searched for:

in-biosketch:true

person:tanejs01

Total Results:

844

Journal of urology. 2015:194(2).DOI: 10.1016/j.juro.2015.05.067

Re: Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Verification of EAU Guideline Criteria [Editorial]

Taneja, Samir S

PMID: 26195365

ISSN: 1527-3792

CID: 1871822

Journal of urology. 2015:194(2).DOI: 10.1016/j.juro.2015.05.064

Re: Screening and Prostate Cancer Mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 Years of Follow-up [Comment]

Taneja, Samir S

PMID: 26195362

ISSN: 1527-3792

CID: 2548592

Journal of urology. 2015:194(2):393-4.DOI: 10.1016/j.juro.2015.05.066

Re: Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-Specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study [Comment]

Taneja, Samir S

PMID: 26195364

ISSN: 1527-3792

CID: 1871692

Journal of urology. 2015:194(1).DOI: 10.1016/j.juro.2015.04.066

Re: Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?

Taneja, Samir S

PMID: 26088225

ISSN: 1527-3792

CID: 1632452

Journal of urology. 2015:194(1):112-5.DOI: 10.1016/j.juro.2015.04.062

Re: Comparison of MR/Ultrasound Fusion-Guided Biopsy with Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer

Taneja, Samir S

PMID: 26088222

ISSN: 1527-3792

CID: 1632422

Journal of urology. 2015:194(1):113-4.DOI: 10.1016/j.juro.2015.04.064

Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data

Taneja, Samir S

PMID: 26088223

ISSN: 1527-3792

CID: 1632432

Journal of urology. 2015:194(1).DOI: 10.1016/j.juro.2015.04.065

Re: Salvage High-Intensity Focused Ultrasound for Patients with Recurrent Prostate Cancer after Brachytherapy

Taneja, Samir S

PMID: 26088224

ISSN: 1527-3792

CID: 1632442

World journal of urology. 2015:33(7):945-53.DOI: 10.1007/s00345-015-1505-8

TOOKAD((R)) Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer

Azzouzi, A R; Barret, E; Bennet, J; Moore, C; Taneja, S; Muir, G; Villers, A; Coleman, J; Allen, C; Scherz, A; Emberton, M

PURPOSE: To evaluate the 6-month effects of the recommended drug and light dosage in focal vascular-targeted photodynamic therapy (VTP) using TOOKAD((R)) Soluble in patients with localized prostate cancer (LPCa). METHODS: We performed a pooled analysis of 117 men with LPCa, PSA <10 ng/mL, and Gleason score /= 1 (N = 67). Mean prostate necroses at week-1 were 76.5 and 86.3 %, respectively. In both groups, PSA levels at month 6 decreased by 2.0 ng/mL. Small changes from baseline for IPSS and IIEF-5 indicated a slight improvement in urinary function and a slight deterioration in sexual function. CONCLUSIONS: Focal VTP treatment with TOOKAD((R)) Soluble at 4 mg/kg and 200 J/cm resulted in a negative 6-month biopsy rate of 68.4 % for the whole population and 80.6 % for patients treated by hemiablation with LDI >/= 1. The treatment was well tolerated. Two phase III studies will reach completion in early 2015.

PMCID:4480329

PMID: 25712310

ISSN: 1433-8726

CID: 1664802

Journal of urology. 2015:193(6):1982-3.DOI: 10.1016/j.juro.2015.03.045

Re: patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer

Taneja, Samir S

PMID: 25986793

ISSN: 1527-3792

CID: 1590792

Journal of urology. 2015:193(6).DOI: 10.1016/j.juro.2015.03.043

Re: Five-Year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer

Taneja, Samir S

PMID: 25986791

ISSN: 1527-3792

CID: 1590772